Zobrazeno 1 - 10 of 19 pro vyhledávání: '"Nehal J Lakhani"'
5
A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: Trial-in-progress update
Autor: Neil Howard Segal, Meredith Pelster, Eugenia Girda, Lawrence Fong, Anthony J. Olszanski, Hyunsil Han, Kerry A. Casey, Siyu Li, Erik Welf, Chieh-I Chen, Dimitris Skokos, Frank A. Seebach, Israel Lowy, Matthew G. Fury, Melissa Divya Mathias, Nehal J. Lakhani
Publikováno v: Journal of Clinical Oncology. 41:TPS277-TPS277
TPS277 Background: There is a need to develop novel immunotherapeutic approaches to enhance responses to immune checkpoint blockade. REGN7075 is a human costimulatory bispecific antibody designed to bridge epidermal growth factor receptor (EGFR)-expr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d2e7998b51b4305472d32f17cf3c3dda
https://doi.org/10.1200/jco.2023.41.4_suppl.tps277
Zobrazit plný text záznamu
6
Abstract CT041: Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1)
Autor: Michael Millward, Justin C. Moser, Diwakar Davar, Mark Voskoboynik, Nehal J. Lakhani, Rachel E. Sanborn, Jaspreet Grewal, Ajita Narayan, Mario Sznol, Keren Schieber, Hany Zayed, Christine Dela Cruz, Graciela Perez, Stanford L. Peng
Publikováno v: Cancer Research. 82:CT041-CT041
Background: Strong preclinical rationale has emerged for combining checkpoint inhibition (CPI) with T cell costimulatory agonists, particularly CD28, a critical T cell costimulatory molecule recognized as a key target of checkpoint inhibition. Davoce
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3575f5aa656a02946482d8104dd06b4b
https://doi.org/10.1158/1538-7445.am2022-ct041
Zobrazit plný text záznamu
7
Efficacy proof-of-concept from a phase 1 study of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ in patients with refractory solid tumors
Autor: T.R. Jeffry Evans, Nehal J. Lakhani, Hendrik-Tobias Arkenau, Meredith McKean, Stefan N. Symeonides, Fabio Massaiti Iwamoto, Jim Rotolo, Gina Capiaux, Rob Michel, Stephen Kaesshaefer, Alice Susannah Bexon, Gerald Steven Falchook
Publikováno v: Journal of Clinical Oncology. 40:3014-3014
3014 Background: The oncogenic transcription factor CCAAT/enhancer-binding protein β (C/EBPβ) promotes tumor survival and proliferation and inhibits differentiation. ST101 is a peptide antagonist of C/EBPβ, with anti-tumor activity in prostate can
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e1eb563063a25cd43a024d324d95bc30
https://doi.org/10.1200/jco.2022.40.16_suppl.3014
Zobrazit plný text záznamu
8
Phase 1 study of SGN-ALPV, a novel, investigational vedotin antibody–drug conjugate directed to ALPP/ALPPL2 in advanced solid tumors (SGNALPV-001, trial in progress)
Autor: Nehal J. Lakhani, Claire Frances Friedman, Cesar Augusto Perez, Alison Wehr, Suzanne M. McGoldrick, Patricia LoRusso
Publikováno v: Journal of Clinical Oncology. 40:TPS3159-TPS3159
TPS3159 Background: Alkaline phosphatase placental (ALPP) and ALPP-like 2 (ALPPL2) are proteins with 98% sequence similarity that are highly expressed in ovarian, endometrial, gastric, and testicular cancers. Restricted normal tissue expression and e
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::18c79534f71ffd62a35a8608ad43a884
https://doi.org/10.1200/jco.2022.40.16_suppl.tps3159
Zobrazit plný text záznamu
9
Dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1)
Autor: Diwakar Davar, Justin C Moser, Michael Millward, Mark Voskoboynik, Nehal J. Lakhani, Rachel E. Sanborn, Jaspreet Singh Grewal, Ajita Narayan, Mario Sznol, Stacey R. Dillon, Keren Schieber, Hany Zayed, Christine Marie Dela Cruz, Graciela Noemi Perez, Stanford L. Peng
Publikováno v: Journal of Clinical Oncology. 40:2560-2560
2560 Background: Strong preclinical rationale supports combining checkpoint inhibition (CPI) with T cell costimulatory agonists, particularly of CD28, a critical T cell costimulatory molecule recognized as a key target of checkpoint inhibition. Davoc
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1071f148035ec891d8858fd5af466b57
https://doi.org/10.1200/jco.2022.40.16_suppl.2560
Zobrazit plný text záznamu
10
ARTISTRY-3: Effect of nemvaleukin alfa with a less frequent IV dosing schedule as monotherapy and in combination with pembrolizumab and impact on the tumor microenvironment (TME) in patients (pts) with advanced solid tumors
Autor: Sarina Anne Piha-Paul, Corrine F. Elliott, Yangchun Du, Julie R. Graham, Monali Desai, MD, Yan Wang, Rita P. Dalal, Nehal J. Lakhani
Publikováno v: Journal of Clinical Oncology. 40:TPS2684-TPS2684
TPS2684 Background: Nemvaleukin alfa (nemvaleukin, ALKS 4230) is a novel engineered cytokine that selectively binds the intermediate-affinity interleukin-2 (IL-2) receptor, preferentially activating and expanding antitumor CD8+ T cells and NK effecto
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::014b83699f8da5f0e0a73bf9b9ba9bd6
https://doi.org/10.1200/jco.2022.40.16_suppl.tps2684
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje